Meeting
2024 ASCO Genitourinary Cancers Symposium
Diagnosis of prostate cancer and benign prostatic hyperplasia based on urinary cell-free DNA methylation characteristics.
Authors
Jindan Luo
Department of Urology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
Jindan Luo , Hang Dong , Haoran Tang , Jiahe Yi , Pan Du , Shidong Jia , Liping Xie
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Diagnostics and Imaging
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 275)
DOI
10.1200/JCO.2024.42.4_suppl.275
Abstract #
275
Poster Bd #
L10
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Evaluating early changes in circulating tumor DNA (ctDNA) tumor fraction (TF) as a value add to PSA in predicting early progression in metastatic castrate resistant prostate cancer (mCRPC).
First Author: Christopher Sweeney
Poster
2024 ASCO Genitourinary Cancers Symposium
Exploring the utility of prostate-derived extracellular vesicles as a urine biomarker for clinically significant prostate cancer.
First Author: Ekamjit Singh Deol
Poster
2024 ASCO Genitourinary Cancers Symposium
Prostate screening for men with inherited risk of developing aggressive prostate cancer: The PATROL study.
First Author: Heather H. Cheng
Poster
2023 ASCO Genitourinary Cancers Symposium
Evaluating technical feasibility of a urine cell-free DNA (cfDNA) NGS assay for identifying biomarkers in bladder cancer.
First Author: Il-Jin Kim